Skip to main content

Intermittent Claudication due to Peripheral Artery Disease: Best Modern Medical and Endovascular Therapeutic Approaches

Current Cardiology Reports volume 17, Article number: 86 (2015) Cite this article

Abstract

Peripheral artery disease (PAD) is ubiquitous in the USA and is associated with a high burden of morbidity and mortality. Clinical manifestations of PAD are broad and range from the asymptomatic patient to intermittent claudication (IC) to critical limb ischemia (CLI). The efficacy of non-invasive treatment strategies for PAD has been well documented. These include smoking cessation, supervised exercise programs, and medical therapy. Strategies for invasive management of PAD are more controversial due to variability in the manifestations of PAD including lesion length, location, severity, and clinical presentation. This has made formal comparative effectiveness of interventional therapies in PAD challenging. The current review aims to summarize the most recent clinical research in the field of PAD in patients with IC, with a focus on the latest studies regarding risk factor modification and endovascular revascularization therapies.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Mozaffarian D et al. Heart disease and stroke statistics-2015 update: a report from the American Heart Association. Circulation. 2015;131(4):e29–e322. This update from the American Heart Association underlines the continued morbidity and mortality associated with peripheral artery disease.

    Article  PubMed  Google Scholar 

  2. Hirsch AT et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation. 2006;113(11):e463–654.

    Article  PubMed  Google Scholar 

  3. Diehm C et al. Mortality and vascular morbidity in older adults with asymptomatic versus symptomatic peripheral artery disease. Circulation. 2009;120(21):2053–61.

    Article  PubMed  Google Scholar 

  4. Agarwal S. The association of active and passive smoking with peripheral arterial disease: results from NHANES 1999-2004. Angiology. 2009;60(3):335–45.

    Article  PubMed  Google Scholar 

  5. Criqui MH. Peripheral arterial disease—epidemiological aspects. Vasc Med. 2001;6(3 Suppl):3–7.

    CAS  Article  PubMed  Google Scholar 

  6. Cole CW et al. Cigarette smoking and peripheral arterial occlusive disease. Surgery. 1993;114(4):753–6. discussion 756-7.

    CAS  PubMed  Google Scholar 

  7. Faulkner KW, House AK, Castleden WM. The effect of cessation of smoking on the accumulative survival rates of patients with symptomatic peripheral vascular disease. Med J Aust. 1983;1(5):217–9.

    CAS  PubMed  Google Scholar 

  8. Jonason T, Bergstrom R. Cessation of smoking in patients with intermittent claudication. Effects on the risk of peripheral vascular complications, myocardial infarction and mortality. Acta Med Scand. 1987;221(3):253–60.

    CAS  Article  PubMed  Google Scholar 

  9. Lassila R, Lepantalo M. Cigarette smoking and the outcome after lower limb arterial surgery. Acta Chir Scand. 1988;154(11-12):635–40.

    CAS  PubMed  Google Scholar 

  10. Hennrikus D et al. Effectiveness of a smoking cessation program for peripheral artery disease patients: a randomized controlled trial. J Am Coll Cardiol. 2010;56(25):2105–12.

    Article  PubMed  Google Scholar 

  11. Huen KH et al. Smoking cessation is the least successful outcome of risk factor modification in uninsured patients with symptomatic peripheral arterial disease. Ann Vasc Surg. 2015;29(1):42–9. This paper showed that despite meeting other target driven goals such as A1c or blood pressure and LDL targets, that the uninsured were largely unable to quit smoking.

    Article  PubMed  Google Scholar 

  12. Rooke TW et al. 2011 ACCF/AHA focused update of the guideline for the management of patients with peripheral artery disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society for Vascular Medicine, and Society for Vascular Surgery. J Vasc Surg. 2011;54(5):e32–58.

    Article  PubMed  Google Scholar 

  13. Halpern SD et al. Randomized trial of four financial-incentive programs for smoking cessation. N Engl J Med. 2015;372(22):2108–17. This study uses innovative incentivized programs to change behavior. In this case, financial reward for continued smoking abstinence had better success than a deposit based approach. This data sparks intriguing ideas for application in smoking counseling cessation.

    Article  PubMed  Google Scholar 

  14. Lane R et al. Exercise for intermittent claudication. Cochrane Database Syst Rev. 2014;7:CD000990.

    PubMed  Google Scholar 

  15. Fokkenrood HJ et al. Supervised exercise therapy versus non-supervised exercise therapy for intermittent claudication. Cochrane Database Syst Rev. 2013;8:CD005263. This Cochrane review contintues to highlight the improved functional capacity in patients in supervised exercise programs as compared to unsupervised programs. This data in affirmation with prior studies continue to support referral to a supervised exercise program for those patient with symptomatic peripheral arterial disease.

    PubMed  Google Scholar 

  16. Murphy TP et al. Supervised exercise versus primary stenting for claudication resulting from aortoiliac peripheral artery disease: six-month outcomes from the claudication: exercise versus endoluminal revascularization (CLEVER) study. Circulation. 2012;125(1):130–9.

    PubMed Central  Article  PubMed  Google Scholar 

  17. Murphy TP et al. Supervised exercise, stent revascularization, or medical therapy for claudication due to aortoiliac peripheral artery disease: the CLEVER study. J Am Coll Cardiol. 2015;65(10):999–1009.

    Article  PubMed  Google Scholar 

  18. Fakhry F et al. Long-term clinical effectiveness of supervised exercise therapy versus endovascular revascularization for intermittent claudication from a randomized clinical trial. Br J Surg. 2013;100(9):1164–71.

    CAS  Article  PubMed  Google Scholar 

  19. Society for Vascular Surgery Lower Extremity Guidelines Writing Group, Conte MS, Pomposelli FB, Clair DG, Geragty PJ, McKinsey JF, et al. Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: management of asymptomatic disease and claudication. J Vasc Surg. 2015;61(3 Suppl):2S–41S.

  20. Committee, C.S. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996;348(9038):1329–39.

    Article  Google Scholar 

  21. Bhatt DL et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354(16):1706–17.

    CAS  Article  PubMed  Google Scholar 

  22. Bhatt DL et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol. 2007;49(19):1982–8.

    Article  PubMed  Google Scholar 

  23. Singer E et al. Effect of aspirin versus clopidogrel on walking exercise performance in intermittent claudication-a double-blind randomized multicenter trial. J Am Heart Assoc. 2012;1(1):51–6.

    PubMed Central  CAS  Article  PubMed  Google Scholar 

  24. Bedenis R et al. Cilostazol for intermittent claudication. Cochrane Database Syst Rev. 2014;10, CD003748.

    PubMed  Google Scholar 

  25. Torngren K et al. Ticagrelor improves peripheral arterial function in patients with a previous acute coronary syndrome. Cardiology. 2013;124(4):252–8.

    CAS  Article  PubMed  Google Scholar 

  26. Ahimastos AA et al. Effect of ramipril on walking times and quality of life among patients with peripheral artery disease and intermittent claudication: a randomized controlled trial. JAMA. 2013;309(5):453–60.

    CAS  Article  PubMed  Google Scholar 

  27. Mehler PS et al. Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes. Circulation. 2003;107(5):753–6.

    Article  PubMed  Google Scholar 

  28. Adler AI et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ. 2000;321(7258):412–9.

    PubMed Central  CAS  Article  PubMed  Google Scholar 

  29. Selvin E et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med. 2004;141(6):421–31.

    CAS  Article  PubMed  Google Scholar 

  30. Althouse AD et al. Favorable effects of insulin sensitizers pertinent to peripheral arterial disease in type 2 diabetes: results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Diabetes Care. 2013;36(10):3269–75.

    PubMed Central  CAS  Article  PubMed  Google Scholar 

  31. Prospective Studies C et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet. 2007;370(9602):1829–39.

    Article  Google Scholar 

  32. Heart Protection Study Collaborative, G. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7–22.

    Article  Google Scholar 

  33. Mohler 3rd ER, Hiatt WR, Creager MA. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation. 2003;108(12):1481–6.

    CAS  Article  PubMed  Google Scholar 

  34. Aronow WS et al. Effect of simvastatin versus placebo on treadmill exercise time until the onset of intermittent claudication in older patients with peripheral arterial disease at six months and at one year after treatment. Am J Cardiol. 2003;92(6):711–2.

    CAS  Article  PubMed  Google Scholar 

  35. Simmons A, Steffen K, Sanders S. Medical therapy for peripheral arterial disease. Curr Opin Cardiol. 2012;27(6):592–7.

    Article  PubMed  Google Scholar 

  36. Stoekenbroek RM et al. High-dose atorvastatin is superior to moderate-dose simvastatin in preventing peripheral arterial disease. Heart. 2015;101(5):356–62.

    CAS  Article  PubMed  Google Scholar 

  37. Norgren L et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg. 2007;33 Suppl 1:S1–S75.

    Article  PubMed  Google Scholar 

  38. Klein AJ et al. SCAI expert consensus statement for femoral-popliteal arterial intervention appropriate use. Catheter Cardiovasc Interv. 2014;84(4):529–38.

    Article  PubMed  Google Scholar 

  39. Klein AJ et al. SCAI expert consensus statement for aorto-iliac arterial intervention appropriate use. Catheter Cardiovasc Interv. 2014;84(4):520–8.

    Article  PubMed  Google Scholar 

  40. Gray BH et al. SCAI expert consensus statement for infrapopliteal arterial intervention appropriate use. Catheter Cardiovasc Interv. 2014;84(4):539–45.

    Article  PubMed  Google Scholar 

  41. Tewksbury R, et al. Outcomes of covered expandable stents for the treatment of TASC D aorto-iliac occlusive lesions. Vascular. 2015. doi:10.1177/1708538114568479.

  42. Mwipatayi BP et al. A comparison of covered vs bare expandable stents for the treatment of aortoiliac occlusive disease. J Vasc Surg. 2011;54(6):1561–70.

    Article  PubMed  Google Scholar 

  43. Humphries MD et al. Outcomes of covered versus bare-metal balloon-expandable stents for aortoiliac occlusive disease. J Vasc Surg. 2014;60(2):337–43.

    Article  PubMed  Google Scholar 

  44. Kang JL et al. Common femoral artery occlusive disease: contemporary results following surgical endarterectomy. J Vasc Surg. 2008;48(4):872–7.

    Article  PubMed  Google Scholar 

  45. Ballotta E et al. Common femoral artery endarterectomy for occlusive disease: an 8-year single-center prospective study. Surgery. 2010;147(2):268–74.

    Article  PubMed  Google Scholar 

  46. Derksen WJ et al. Risk factors for surgical-site infection following common femoral artery endarterectomy. Vasc Endovasc Surg. 2009;43(1):69–75.

    Article  Google Scholar 

  47. Bonvini RF et al. Angioplasty and provisional stent treatment of common femoral artery lesions. J Vasc Interv Radiol. 2013;24(2):175–83.

    Article  PubMed  Google Scholar 

  48. Soga Y et al. Clinical outcome after endovascular treatment for isolated common femoral and popliteal artery disease. Cardiovasc Interv Ther. 2013;28(3):250–7. This paper shows the technical feasibility and relative high secondary patency rates of percutaneous interventions in the CFA region.

    CAS  Article  PubMed  Google Scholar 

  49. Dake MD et al. Sustained safety and effectiveness of paclitaxel-eluting stents for femoropopliteal lesions: 2-year follow-up from the Zilver PTX randomized and single-arm clinical studies. J Am Coll Cardiol. 2013;61(24):2417–27. This study showed 2 year outcomes for patients undergoing drug eluting stents in the SFA showing superior primary patency compared to balloon angioplasty alone or balloon angioplasty followed by bare metal stent placement.

    CAS  Article  PubMed  Google Scholar 

  50. Tepe G et al. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial. Circulation. 2015;131(5):495–502. This randomized trial showed superiority of drug eluting balloon therapy versus balloon angioplasty in symptomatic SFA disease.

    PubMed Central  CAS  Article  PubMed  Google Scholar 

  51. Scheinert D et al. Paclitaxel-releasing balloon in femoropopliteal lesions using a BTHC excipient: twelve-month results from the BIOLUX P-I randomized trial. J Endovasc Ther. 2015;22(1):14–21.

    Article  PubMed  Google Scholar 

  52. Liistro F et al. Paclitaxel-eluting balloon vs. standard angioplasty to reduce recurrent restenosis in diabetic patients with in-stent restenosis of the superficial femoral and proximal popliteal arteries: the DEBATE-ISR study. J Endovasc Ther. 2014;21(1):1–8.

    Article  PubMed  Google Scholar 

  53. Rosenfield K, et al. Trial of paclitaxel-coated balloon for femoropopliteal artery disease. NEJM. 2015;373(2):145–53. This study shows the superiority of drug coated balloons in terms of primary patency in 2 year follow up as compared to balloon angioplasty.

  54. Herten M et al. Drug-eluting balloons for femoropopliteal lesions show better performance in de novo stenosis or occlusion than in restenosis. J Vasc Surg. 2015;61(2):394–9.

    Article  PubMed  Google Scholar 

  55. Virga V et al. Drug-eluting balloons for the treatment of the superficial femoral artery in-stent restenosis: 2-year follow-up. JACC Cardiovasc Interv. 2014;7(4):411–5.

    Article  PubMed  Google Scholar 

  56. Lichtenberg M et al. PEACE I all-comers registry: patency evaluation after implantation of the 4-French Pulsar-18 self-expanding nitinol stent in femoropopliteal lesions. J Endovasc Ther. 2014;21(3):373–80.

    Article  PubMed  Google Scholar 

  57. Matsumura JS et al. The United States Study for evaluating endovascular treatments of lesions in the superficial femoral artery and proximal popliteal by using the protege everflex nitinol stent system II (DURABILITY II). J Vasc Surg. 2013;58(1):73–83 e1.

    Article  PubMed  Google Scholar 

  58. Fusaro M et al. Paclitaxel-coated balloon or primary bare nitinol stent for revascularization of femoropopliteal artery: a meta-analysis of randomized trials versus uncoated balloon and an adjusted indirect comparison. Int J Cardiol. 2013;168(4):4002–9. This meta-analysis underscores the efficacy of the bare metal nitinol stents as compared to the standard balloon angioplasty and may perform as well as drug coated balloons in the SFA.

    Article  PubMed  Google Scholar 

  59. Geraghty PJ et al. Three-year results of the VIBRANT trial of VIABAHN endoprosthesis versus bare nitinol stent implantation for complex superficial femoral artery occlusive disease. J Vasc Surg. 2013;58(2):386–95 e4. The long term outcomes of this study add to the growing data that covered stents perform just as well as bare metal stents in complex SFA disease though both study groups had low primary patency rates.

    Article  PubMed  Google Scholar 

  60. Lammer J et al. Sustained benefit at 2 years for covered stents versus bare-metal stents in long SFA lesions: the VIASTAR trial. Cardiovasc Intervent Radiol. 2015;38(1):25–32.

    Article  PubMed  Google Scholar 

  61. Vartanian SM et al. Clinical consequence of bare metal stent and stent graft failure in femoropopliteal occlusive disease. J Vasc Surg. 2013;58(6):1525–31.

    Article  PubMed  Google Scholar 

  62. Goueffic Y et al. Bare metal stent versus paclitaxel eluting stent for intermediate length femoropopliteal arterial lesions (BATTLE trial): study protocol for a randomized controlled trial. Trials. 2014;15:423.

    PubMed Central  Article  PubMed  Google Scholar 

  63. McKinsey JF et al. Lower extremity revascularization using directional atherectomy: 12-month prospective results of the DEFINITIVE LE study. JACC Cardiovasc Interv. 2014;7(8):923–33.

    Article  PubMed  Google Scholar 

  64. Dippel EJ et al. Randomized controlled study of excimer laser atherectomy for treatment of femoropopliteal in-stent restenosis: initial results from the EXCITE ISR trial (EXCImer Laser Randomized Controlled Study for Treatment of FemoropopliTEal In-Stent Restenosis). JACC Cardiovasc Interv. 2015;8(1 Pt A):92–101. This randomized control trial examining laser atherectomy and angioplasty showed a significant benefit in 6 month freedom from total limb revascularization and major adverse events at 30 days when compared to angioplasty alone.

    Article  PubMed  Google Scholar 

  65. Marmagkiolis K et al. 12-month primary patency rates of contemporary endovascular device therapy for femoro-popliteal occlusive disease in 6,024 patients: beyond balloon angioplasty. Catheter Cardiovasc Interv. 2014;84(4):555–64. This study examines the primary patency rates across multiple endovascular approaches in femoro-popliteal disease. The main finding in this study is that there is so much variability in the severity and location of disease being treated that it is currently impossible to compare all the current modalities of endovascular interventions.

    Article  PubMed  Google Scholar 

  66. Rastan A et al. Sirolimus-eluting stents for treatment of infrapopliteal arteries reduce clinical event rate compared to bare-metal stents: long-term results from a randomized trial. J Am Coll Cardiol. 2012;60(7):587–91.

    CAS  Article  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Taisei Kobayashi and Jay Giri declare that they have no conflict of interest. Sahil A. Parikh is a consultant for Abbott Vascular, Boston Scientific, and Medtronic. He is on the speaker’s bureau for Abbot Vascular, Boston Scientific, Medtronic, and Angioscore. He has received research grant support from Lutonix/CR Bard, Medtronic, Abbott Vascular, Boston Scientific, TriReme Medical, and Atrium Medical/Maquet.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Affiliations

  1. Cardiovascular Medicine Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

    Taisei Kobayashi & Jay Giri

  2. University Hospitals Harrington Heart and Vascular Institute and Case Western Reserve University School of Medicine, Cleveland, OH, USA

    Sahil A. Parikh

  3. Hospital of the University of Pennsylvania, 3400 Spruce Street Gates 9, Philadelphia, PA, 19104, USA

    Jay Giri

Authors
  1. Taisei Kobayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sahil A. Parikh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jay Giri
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jay Giri.

Additional information

This article is part of the Topical Collection on Peripheral Vascular Disease

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Kobayashi, T., Parikh, S.A. & Giri, J. Intermittent Claudication due to Peripheral Artery Disease: Best Modern Medical and Endovascular Therapeutic Approaches. Curr Cardiol Rep 17, 86 (2015). https://doi.org/10.1007/s11886-015-0643-3

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11886-015-0643-3

Keywords

  • Intermittent claudication
  • Peripheral artery disease
  • Peripheral arterio-occlusive disease
  • Endovascular intervention